Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Screening for gHgLgO interaction partners reveals decreased binding of the gO249 mutant to cell surfaces. by Lena Thiessen (17605194)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Mean observer DCCR (%) and DDR (%) at C2-3 in neutral (n = 22) and flexed (n = 18) neck positions. by Devon England (21262225)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Prolonged starvation leads to a delay in cell cycle re-entry and decrease in H3K27ac in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

“…Significance levels after one-way ANOVA with Tukey’s HSD for pairwise comparisons are indicated for adjusted <i>p</i> values: *<i>p < </i>0.05, **<i>p < </i>0.01; ****<i>p < </i>0.0001. d: day(s), n.s.: non-significant. …”

Phylogenetic distance between partial pol-wgs mixtures and nFL genome for subset dataset. by August Guang (9975678)

Subjects:

Phylogenetic distance between partial pol-wgs mixtures and nFL genome for full dataset. by August Guang (9975678)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Maximum and mean SL values of the call types. by Anna N. Osiecka (11739336)

Cement retention force values(N) for each group in the cement retention strength test. by Long Li (6555)